Filing Flows

Filing Flows › Teleflex (TFX) › Recalls, complaints & regulation

Teleflex (TFX): recalls, EPA violations and clinical trials

Teleflex (TFX) beyond its filings: 1 recall in the last 12 months (149 in five years, 136 Class I); 1 EPA-regulated facility in violation, $40K in penalties over five years; 4 active clinical trials.

Latest recalls

EPA facilities in violation

Facility (as registered)CityStatusPenalties
TELEFLEX MEDICAL INCDurham, NCSignificant Violation—

Facilities in the EPA's ECHO register whose registered name matches the company's; a facility can belong to another business of the same name.

Teleflex's latest quarter

Teleflex, Q3 2026: revenue $568M (+0.1% year over year), operating margin 18.6%, net earnings $927M, operating cash flow $96.3M. The chart follows the revenue to costs, profit and cash.

Questions

Has Teleflex had any recalls?

149 recalls on file over five years from the FDA, CPSC and NHTSA; 1 in the last 12 months.

Has Teleflex been fined by the EPA?

The 21 EPA-regulated facilities on file under its name drew $40K in penalties over five years; 1 is in violation now.

How many clinical trials does Teleflex have?

4 active studies on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.